BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hiru Corporation (HIRU)'s MindUp BioResearch Research Team Published Their New Results on the Topic of Overcoming Multiple-Drug Resistance in Lung Cancer Therapy


8/5/2011 11:07:13 AM

BELGRADE, SERBIA, Aug 04, 2011 (MARKETWIRE via COMTEX) -- Hiru Corporation /quotes/zigman/531972 HIRU -25.00% ( http://www.hirucorporation.com/ ), is pleased to announce that researchers from its MindUp BioResearch ( www.mindupbioresearch.com ), European subsidiary have published their new results of preclinical studies on the topic of overcoming multidrug resistance, a frequent phenomenon occurring in cancer that seriously limit the efficacy of lung cancer course of therapy with chemotherapeutic agents.

Dr Sabera Ruzdijic, the Leader of MindUp Bioresearch Group said: "In this paper we examined the effect of two purine analogs sulfinosine (SF) and 8-Cl-cAMP on cell growth inhibition in parental and resistant human lung carcinoma cell lines. Pretreatment with purine analogues was more potent in improving the sensitivity of resistant lung carcinoma cells to doxorubicin than conventional chemo-sensitizing agent - verapamil (VER). Combinations of either SF or 8-Cl-cAMP with VER at clinically acceptable concentrations exhibited synergistic effects on cell growth inhibition in the resistant lung carcinoma cell line. Together with their ability to reverse multidrug resistance, these results render the purine analogs (in combination with VER) as potential candidates for improving the clinical activity of existing lung cancer therapeutics.

Dr Sabera Ruzdijic added: "We are proud that these results are accepted and published in the prestigious journal Investigational New Drugs (2010) 28:482-492 by Pesic et al. ( http://www.springerlink.com/content/w2h2805230314332/ )". At the company website http://www.hirucorporation.com/ you can find the PDF of article.

In other company news and updates, MindUp division is currently in negotiation discussions as a buyout candidate. The management is of the opinion that this is a material event that warrants a news release.

More details will follow on the MindUp divestiture as it becomes available.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf of Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts:

Hiru Corporation

corporate@hirucorporation.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES